Improvement of peripheral vascular impairment by a phosphodiesterase type 5 inhibitor tadalafil prevents oxaliplatin-induced peripheral neuropathy in mice

Ogihara, Takashi; Nakagawa, Takayuki; Hayashi, Maho; Koyanagi, Madoka; Yonezawa, Atsushi; Omura, Tomohiro; Kitada, Noriaki; Imai, Shoichi; Matsubara, Kazuo

doi:10.1016/j.jphs.2019.10.005

Cited by 19 publications

(13 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Because NIC symptoms in LSS can be partially attributed to vascular compromise, we posit that PDE5i drugs may have potentially alleviated their symptoms because of their effects in augmenting vascular function and axonal remodeling. 19,20 Consequently, active use of PDE5i may have contributed to the decrease in the LDS prevalence, which is a treatment option typically reserved for more severe symptoms.…”

Section: Discussionmentioning

confidence: 99%

Phosphodiesterase 5 Inhibitor Use in Patients Undergoing Decompression Surgery for Lumbar Spinal Stenosis

Pham

Butler

Weideman

et al. 2021

Am J Phys Med Rehabil

View full text Add to dashboard Cite

This study was partly funded by the Rehabilitation Research Experience for Medical Students of the Association of Academic Physiatrists. The results of this study were presented at Physiatry '21, the Virtual Annual Meeting of the Association of Academic Physiatrists, February 13, 2021. Tri Pham and Adam Butler are in training. Financial disclosure statements have been obtained, and no conflicts of interest have been

show abstract

Section: Discussionmentioning

confidence: 99%

Phosphodiesterase 5 Inhibitor Use in Patients Undergoing Decompression Surgery for Lumbar Spinal Stenosis

Pham

Butler

Weideman

et al. 2021

Am J Phys Med Rehabil

View full text Add to dashboard Cite

show abstract

“…While the mechanisms of accumulation of chemotherapy agents in dorsal root ganglion neurons is unknown, some evidence shows that the accumulation of platinum derivates may be due to high expression of specific membrane transporters, such as the organic anion-transporting polypeptides (OATPs), and the organic cation transporter (OCT) that are responsible for platinum transport (Gregg et al, 1992;Screnci et al, 2000;Fujita et al, 2019;. Studies in animals and humans have also shown that the prolonged use of chemotherapeutic agents such as vincristine, oxaliplatin, cisplatin, carboplatin, paclitaxel, bortezomib and ixabepilone can result in degeneration of large, myelinated axons and the loss of intraepidermal nerve fibers (Sahenk et al, 1994;Neijt et al, 2000;Parmar et al, 2003;Boyette-Davis et al, 2013;Boehmerle et al, 2014;Ebenezer et al, 2014;Yamamoto et al, 2015a;Geisler et al, 2016;Turkiew et al, 2017;Malacrida et al, 2019;Ogihara et al, 2019). The extent of neuronal damage has been correlated with different degrees of neuropathy severity, but the precise underlying mechanisms by which demyelination and degeneration of peripheral nerves contribute to CIPN remain unclear (Colvin, 2019;Malacrida et al, 2019).…”

Section: Neuronal Damagementioning

confidence: 99%

Chemotherapy-induced peripheral neuropathy in children and adolescent cancer patients

Tay

Laakso

Schweitzer

et al. 2022

Front. Mol. Biosci.

View full text Add to dashboard Cite

Brain cancer and leukemia are the most common cancers diagnosed in the pediatric population and are often treated with lifesaving chemotherapy. However, chemotherapy causes severe adverse effects and chemotherapy-induced peripheral neuropathy (CIPN) is a major dose-limiting and debilitating side effect. CIPN can greatly impair quality of life and increases morbidity of pediatric patients with cancer, with the accompanying symptoms frequently remaining underdiagnosed. Little is known about the incidence of CIPN, its impact on the pediatric population, and the underlying pathophysiological mechanisms, as most existing information stems from studies in animal models or adult cancer patients. Herein, we aim to provide an understanding of CIPN in the pediatric population and focus on the 6 main substance groups that frequently cause CIPN, namely the vinca alkaloids (vincristine), platinum-based antineoplastics (cisplatin, carboplatin and oxaliplatin), taxanes (paclitaxel and docetaxel), epothilones (ixabepilone), proteasome inhibitors (bortezomib) and immunomodulatory drugs (thalidomide). We discuss the clinical manifestations, assessments and diagnostic tools, as well as risk factors, pathophysiological processes and current pharmacological and non-pharmacological approaches for the prevention and treatment of CIPN.

show abstract

“…Animal and human studies have demonstrated that the longterm use of the platinum derivatives [62,63] paclitaxel [64], vincristine [65], and bortezomib [66] can induce axonal degeneration, specifically, the loss of large myelinated, small unmyelinated and intra-epidermal nerve fibers. The loss of myelin and changes to the axonal cytoskeleton may alter the structure and impair the function of peripheral nerves, thus leading to the development of sensory and motor peripheral neuropathy and altered pain perception.…”

Section: Axonal Degenerationmentioning

confidence: 99%

Chemotherapy-induced peripheral neuropathy: part 1—current state of knowledge and perspectives for pharmacotherapy

Sałat

2020

Pharmacol. Rep

View full text Add to dashboard Cite

Background Despite the increasing knowledge of the etiology of neuropathic pain, this type of chronic pain is resistant to available analgesics in approximately 50% of patients and therefore is continuously a subject of considerable interest for physiologists, neurologists, medicinal chemists, pharmacologists and others searching for more effective treatment options for this debilitating condition. Materials and methods The present review article is the first of the two articles focused on chemotherapy-induced peripheral neuropathy (CIPN). Results CIPN is regarded as one of the most common drug-induced neuropathies and is highly pharmacoresistant. The lack of efficacious pharmacological methods for treating CIPN and preventing its development makes CIPN-related neuropathic pain a serious therapeutic gap in current medicine and pharmacotherapy. In this paper, the most recent advances in the field of studies on CIPN caused by platinum compounds (namely oxaliplatin and cisplatin), taxanes, vinca alkaloids and bortezomib are summarized. Conclusions The prevalence of CIPN, potential causes, risk factors, symptoms and molecular mechanisms underlying this pharmacoresistant condition are discussed.

show abstract

Improvement of peripheral vascular impairment by a phosphodiesterase type 5 inhibitor tadalafil prevents oxaliplatin-induced peripheral neuropathy in mice

Cited by 19 publications

References 39 publications

Phosphodiesterase 5 Inhibitor Use in Patients Undergoing Decompression Surgery for Lumbar Spinal Stenosis

Phosphodiesterase 5 Inhibitor Use in Patients Undergoing Decompression Surgery for Lumbar Spinal Stenosis

Chemotherapy-induced peripheral neuropathy in children and adolescent cancer patients

Chemotherapy-induced peripheral neuropathy: part 1—current state of knowledge and perspectives for pharmacotherapy

Contact Info

Product

Resources

About